Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study
- PMID: 15077310
- DOI: 10.1002/art.20176
Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study
Abstract
Objective: This study was undertaken to analyze standardized mortality ratios (SMRs) and causes and predictors of death in primary Sjögren's syndrome (SS) diagnosed according to 3 different classification criteria sets (the Copenhagen criteria, the European criteria, and the American-European consensus criteria (AECC).
Methods: A linked registry study using information from the Malmö Primary SS Registry combined with the Swedish Cause-of-Death Registry was performed, and SMRs were calculated. Kaplan-Meier survival curves and log rank tests were used to compare survival probability between subgroups of patients with primary SS. Cox regression analysis was used to study the predictive value of various laboratory findings at the time of diagnosis.
Results: Four hundred eighty-four patients with a median followup of 7 years (range 1 month to 17 years 11 months) were included. The SMR for those fulfilling the AECC (n = 265) was 1.17 (95% confidence interval [95% CI] 0.81-1.63). Thirty-four deaths occurred in this group of patients. Excess mortality was found only for lymphoproliferative malignancy (cause-specific SMR 7.89 [95% CI 2.89-17.18]), corresponding to 2.53 excess deaths per 1,000 person-years at risk. In those not fulfilling the AECC (n = 219), 14 deaths occurred, the SMR was 0.71 (95% CI 0.39-1.20), and no excess mortality due to any specific cause was found. Hypocomplementemia, defined as C3 and/or C4 values in the lowest quartile of the SS patients' values at the time of diagnosis, was a significant predictor of death, mainly due to lymphoproliferative malignancy.
Conclusion: No increased all-cause mortality could be detected for patients with primary SS compared with the general population. When subgroups of primary SS were compared, excess mortality due to lymphoproliferative malignancy was found in patients fulfilling the AECC, the strongest predictor for unfavorable outcome being low C3 and/or C4 levels at the time of diagnosis.
Comment in
-
Concerns about the prevalence of primary Sjögren's syndrome: comment on the article by Theander et al.Arthritis Rheum. 2005 Jan;52(1):369; author reply 369-70. doi: 10.1002/art.20774. Arthritis Rheum. 2005. PMID: 15641056 No abstract available.
Similar articles
-
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.Arthritis Rheum. 2002 Mar;46(3):741-7. doi: 10.1002/art.10221. Arthritis Rheum. 2002. PMID: 11920410
-
Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome.Rheumatology (Oxford). 2005 Jan;44(1):89-94. doi: 10.1093/rheumatology/keh407. Epub 2004 Sep 20. Rheumatology (Oxford). 2005. PMID: 15381790
-
Survivorship in a population based cohort of patients with Sjögren's syndrome, 1976-1992.J Rheumatol. 1999 Jun;26(6):1296-300. J Rheumatol. 1999. PMID: 10381046
-
Epidemiology of primary Sjögren's syndrome in north-west Greece, 1982-2003.Rheumatology (Oxford). 2006 Feb;45(2):187-91. doi: 10.1093/rheumatology/kei107. Epub 2005 Dec 6. Rheumatology (Oxford). 2006. PMID: 16332955 Review.
-
Exocrine function in primary Sjögren syndrome: natural course and prognostic factors.Ann Rheum Dis. 2008 Jul;67(7):949-54. doi: 10.1136/ard.2007.074203. Epub 2007 Oct 25. Ann Rheum Dis. 2008. PMID: 17962240 Review.
Cited by
-
Immunometabolic alteration of CD4+ T cells in the pathogenesis of primary Sjögren's syndrome.Clin Exp Med. 2024 Jul 22;24(1):163. doi: 10.1007/s10238-024-01429-6. Clin Exp Med. 2024. PMID: 39039306 Free PMC article.
-
Recommendations on cutaneous and hematological manifestations of Sjögren's disease by the Brazilian Society of Rheumatology.Adv Rheumatol. 2024 Jul 9;64(1):51. doi: 10.1186/s42358-024-00391-x. Adv Rheumatol. 2024. PMID: 38982553
-
The association between primary Sjogren's syndrome and non-Hodgkin's lymphoma: a systematic review and meta-analysis of cohort studies.Clin Rheumatol. 2024 Jul;43(7):2177-2186. doi: 10.1007/s10067-024-06993-6. Epub 2024 May 9. Clin Rheumatol. 2024. PMID: 38722505 Review.
-
Epidemiology of Sjögren syndrome.Nat Rev Rheumatol. 2024 Mar;20(3):158-169. doi: 10.1038/s41584-023-01057-6. Epub 2023 Dec 18. Nat Rev Rheumatol. 2024. PMID: 38110617 Review.
-
Mortality associated with Sjögren's syndrome in the United States in the 1999-2020 period: A multiple cause-of-death study.Open Med (Wars). 2023 Oct 30;18(1):20230829. doi: 10.1515/med-2023-0829. eCollection 2023. Open Med (Wars). 2023. PMID: 38025530 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
